Tau-PET is elevated in the cortex of patients who are positive for amyloid biomarkers and allows differentiation of patients with AD from controls or patients with other neurodegenerative diseases with high accuracy [109]. The gene discussed is MAPT; the disease is neurodegenerative disease.